Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announces that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track record of innovation in the unit dose nasal spray market. The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva’s ability to serve biopharma customers across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).
Read the full article: Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization //
Source: https://www.businesswire.com/news/home/20240117554516/en/Kindeva-Drug-Delivery-Acquires-Summit-Biosciences-a-Specialized-Nasal-Drug-Development-and-Manufacturing-Organization